Reputable Immunologist Joins Scientific Advisory Board at NextGen
April 10 2008 - 6:30AM
Marketwired
LONDON, UNITED KINGDOM (PINK SHEETS: NXGB), a biotechnology
company that develops novel therapeutic proteins that disrupt the
advance of life-threatening cancers, today announced that Professor
William H. Stimson of Scotland is joining its International
Scientific Advisory Board.
"We are most fortunate to have William H. Stimson join our
Scientific Advisory Board," stated Konstantinos Kardiasmenos, CEO
of NextGen. "Professor Stimson, who is considered to be a world
leader in cancer research, will be an invaluable asset to NextGen
as we continue to develop and license cancer-fighting proteins. He
will play a key role in providing scientific advice in the research
and development of NextGen's emerging product portfolio,
specifically in the areas of immunological and biochemical
processes."
About Professor William H. Stimson (BSc., PhD., Cbiol., FIBiol.,
FioN., FWIF, FRSE)
Professor Stimson is an internationally recognized expert in the
field of molecular recognition of antibodies. He was previously the
Head of the Department of Immunology (which he formed in 1984) at
the University of Strathclyde, in Glasgow, Scotland, and now holds
the position of Chair of Immunology, Division of Immunology,
Microbiology and Biochemistry, Strathclyde Institute of Pharmacy
and Biomedical Sciences.
Professor Stimson is also the Chairman at the Institute of
Nanotechnology, UK, and European Chairman of the NanoMedicine
Committee. He sits on several medical journal Editorial Boards, is
a longtime consultant to numerous pharmaceutical multinationals,
has been intimately involved in the formation of eight companies,
has been issued 12 patents, and has published over 200 scientific
papers. Professor Stimson collaborated on the creation of the first
human monoclonal antibody and was instrumental in developing the
present generation of diagnostic systems. In addition to his
university duties, Professor Stimson serves on the Advisory
Management Committee of the Scottish Antibody Production Unit.
Professor Stimson obtained his Ph.D. in Biochemistry at the
University of St. Andrews (Scotland) in 1971.
About NextGen Bioscience Inc.
NextGen is positioning itself as the world's leading bioscience
company in the development and commercial licensure of novel
therapeutic proteins that disrupt the advance of life-threatening
cancers. The company leverages cutting-edge research collaborations
to achieve breakthroughs in anti-cancer treatments, and then
licenses these patented drug product candidates to Big
Pharmaceutical and Biotechnology companies.
At present, NextGen is rapidly building its portfolio of
proprietary biotechnology. Its first two anti-tumor drug
candidates, Prostaganin (prostate cancer) and Tetanolic (breast
cancer) -- both have incredible market potential as they may
ultimatelyeliminate the need for surgery and chemotherapy and
possess no side effects. NextGen's target market --cancer
treatments-- is the largest disease market, exploding at a 20%
growth rate each year. NextGen's treatment niche is based on recent
discoveries that indicate that most tumors are derived from a
single cancer-initiating cell population which has stem cell
properties (a cancer stem cell). NextGen has chosen to concentrate
on identification of certain cell-specific characteristics, making
it possible to identify precursor cells of tumors, and then conduct
a more extensive 'fingerprinting' profile that will enable the
development of cell-specific anti-cancer treatments. This will
result in a 'tailor made' cancer treatment strategy that is
superior to existing therapies in its ability to eradicate
malignant cells whilst leaving healthy tissue intact.
Statements about NextGen's future expectations and all other
statements in this press release other than historical facts are
"forward-looking statements" within the meaning of section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as the term is defined in the Private Litigation
Reform Act of 1995. NextGen's actual results could differ
materially from expected results. NextGen undertakes no obligation
to update forward-looking statements to reflect subsequently
occurring events or circumstances.
For more information about NextGen Bioscience, Inc., or to
schedule an interview with Mr. Kardiasmenos, please contact +44 20
7247 8186 or investorrelations@nextgenbioscience.com.
Contacts: NextGen Bioscience, Inc. Graham May +44 (0) 20 7247
8186 +44 (0) 20 7377 9454 (FAX) Email:
investorrelations@nextgenbioscience.com Website:
www.nextgenbioscience.com
NxGen Brands (PK) (USOTC:NXGB)
Historical Stock Chart
From Mar 2024 to Apr 2024
NxGen Brands (PK) (USOTC:NXGB)
Historical Stock Chart
From Apr 2023 to Apr 2024